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Abstract
Ectopic pregnancy (EP) is difficult to diagnose early and accurately. Women often present at emergency departments in
early pregnancy with a ‘pregnancy of unknown location’ (PUL), and diagnosis and exclusion of EP is challenging due to a
lack of reliable biomarkers. The objective of this study was to identify novel diagnostic biomarkers for EP. Shotgun
proteomics, incorporating combinatorial-ligand library pre-fractionation, was used to interrogate pooled sera (n = 40) from
women undergoing surgery for EP, termination of viable intrauterine pregnancy and management of non-viable
intrauterine pregnancy. Western blot was used to validate results in individual sera. ELISAs were developed to interrogate
sera from women with PUL (n = 120). Sera were collected at time of first symptomatic presentation and categorized
according to pregnancy outcome. The main outcome measures were differences between groups and area under the
receiver operating curve (ROC). Proteomics identified six biomarker candidates. Western blot detected significant
differences in levels of two of these candidates. ELISA of sera from second cohort revealed that these differences were only
significant for one of these candidates, fibronectin. ROC analysis of ability of fibronectin to discriminate EP from other
pregnancy outcomes suggested that fibronectin has diagnostic potential (ROC 0.6439; 95% CI 0.5090 to 0.7788; P.0.05),
becoming significant when ‘ambiguous’ medically managed PUL excluded from analysis (ROC 0.6538; 95% CI 0.5158 to
0.7918; P,0.05). Fibronectin may make a useful adjunct to future multiplex EP diagnostic tests.
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Introduction
Ectopic pregnancy occurs when the conceptus implants and
develops outside the uterine cavity, with the vast majority of cases
occurring in the Fallopian tube [1,2]. It complicates 1–2% of
pregnancies, causing significant maternal morbidity and occasion-
al mortality [3,4]. Diagnosis of ectopic pregnancy continues to
present a major challenge, with patients often asymptomatic or
presenting with non-specific symptoms that do not readily
differentiate ectopic pregnancy from intrauterine pregnancy.
Whilst in many cases, an ectopic pregnancy will be detected by
transvaginal ultrasonography at the first clinic visit [5], transvag-
inal ultrasonography is often inconclusive and an initial diagnosis
of ‘‘pregnancy of unknown location’’ (PUL) is made [6]. In
patients with a PUL, subsequent diagnosis of ectopic pregnancy
relies on the serial measurement of serum human chorionic
gonadotrophin levels (and, in some centers, progesterone),
together with follow-up transvaginal ultrasonography [3,4,7]. This
approach is expensive, resource intense and significantly delays
diagnosis and management of ectopic pregnancy, increasing the
risk of tubal rupture and life-threatening intra-abdominal haem-
orrhage [8]. There remains an unmet need for a diagnostic test
capable of identifying ectopic pregnancy at first clinical presen-
tation, with a blood test or similar minimally invasive test being the
ultimate goal [7,9].
Nearly 30 candidate serum biomarkers of ectopic pregnancy
have been identified based on their etiological roles in ectopic
pregnancy [10–16]. However, this hypothesis-driven approach has
been slow to generate new candidates and has yet to deliver a
diagnostic test that has been fully validated for use in the clinic.
Unbiased global genomic and proteomic approaches offer a
quicker route to novel biomarker discovery. For example,
microarray analysis of the gene expression profile of endometrium
from patients with ectopic pregnancy has yielded a number of
promising leads [17–19], with serum levels of activin B appearing
to differentiate ectopic pregnancy from both viable and non-viable
intrauterine pregnancy, albeit in a relatively small population [17].
Nevertheless, it is the ability to interrogate the proteome of
biological specimens directly, and with ever increasing degrees of
sophistication, that holds the greatest promise for rapid identifi-
cation of novel biomarkers of ectopic pregnancy. A recent global
proteomic study, employing multidimensional separation together
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with trypsin digestion and quantitative MS/MS to compare sera
from women with ectopic pregnancy versus viable intrauterine
pregnancy, has almost doubled the list of previously published
potential biomarkers [20]. However, when women present with
pain and/or bleeding and a PUL there are more than two
potential final outcomes. Here, we describe the identification of a
candidate biomarker of ectopic pregnancy employing a commer-
cial combinatorial ligand library (ProteoMinerTM, BIO-RAD) to
facilitate the identification for novel low-medium abundance
biomarkers using a shotgun proteomics approach [21]. Initially,
we compared sera collected retrospectively from women with
known pregnancy outcomes of ectopic pregnancy, viable intra-
uterine pregnancy and non-viable intrauterine pregnancy. We
then tested candidate biomarkers of ectopic pregnancy informed
by our proteomic data in a separate, well-defined, prospective
case-control study that included every possible PUL final outcome,
not only ectopic pregnancy and viable intrauterine pregnancy.
Results
Sample Separation and PMF of Differentially Expressed
Bands
Pooled sera collected from women during surgical management
of ectopic pregnancy (EP: confirmed at surgery and by pathology;
n = 15); nonviable intrauterine pregnancy (NVIUP: USS-con-
firmed intrauterine gestational sac with yolk sac and/or embryo
without cardiac activity seen prior to uterine evacuation: n = 10);
and termination of viable intrauterine pregnancy (VIUP: USS-
confirmed intrauterine gestational sac with an embryo with
cardiac activity seen prior to uterine evacuation; n = 15), were
pre-fractionated using ProteoMinerTM spin-columns and separat-
ed by SDS-PAGE, alongside whole sera and unbound flow-
through from the spin-columns (Figure 1). Lanes loaded with
ProteoMinerTM enriched fractions contained more protein bands
than those loaded with whole sera or unbound flow-through from
the spin-columns. By contrast, only minor differences were
observed between lanes loaded with whole sera and flow-through,
suggesting that the vast majority of serum proteins that are
normally visible by SDS-PAGE saturate the ProteoMinerTM spin-
columns and were preferentially depleted from the enriched
fractions. Comparison of the three patient groups revealed distinct
bands in ProteoMinerTM enriched (B1 and B2) and whole serum
(B3) fractions that appeared to be differentially expressed in the EP
group. B1 appeared to be reduced in the EP group, whereas B2
and B3 both appear to be more abundant in the EP group. All
three bands were excised and submitted for PMF by MALDI-
TOF. Definitive results were obtained for B1, which was identified
as FN1 (Mascot Score 377; 52/88 tryptic peptides assigned to
FN1; 34.0% sequence coverage; Predicted MW 266.1 KDa).
Positive identities were subsequently obtained for B2 (C reactive
protein (CRP): Mascot score 414; 7 unique tryptic peptide spectra
containing four or more contiguous ‘y’ or ‘b’ ions; 27.7% sequence
coverage; Predicted MW 25.0 KDa) and B3 (hemoglobin subunit
beta (HBB): Mascot score 650; 10 unique tryptic peptide spectra
containing four or more contiguous ‘y’ or ‘b’ ions; 75.5% sequence
coverage; Predicted MW 16.0 KDa) using LC-ESI-MS/MS.
Predicted and observed molecular weights were consistent in all
three cases (Figure 1).
Shotgun LC-ESI-MS/MS
Shotgun LC-ESI-MS/MS analysis was performed on Proteo-
MinerTM enriched fractions following SDS-PAGE. After decon-
volution of raw MS/MS data, interrogation of the SwissProt
database produced a total of 1412 non-redundant identities (Table
S1). Filtering of these results, such that protein identities were
based on the assignment of at least two unique peptide spectra
containing a series of four or more contiguous ‘y’ or ‘b’ ions,
reduced this number to 118 high confidence identities (Figure 2).
Of these: 75 were common to all three patient groups; a further 12
were present in the EP group and either the VIUP or NVIUP
groups; 6 were unique to the EP group; 2 were uniquely absent
from the EP group; and a further 5 and 18 were unique to the
VIUP and NVIUP groups respectively. Following exclusion of
potential environmental contaminants (various cytokeratin iso-
forms and trypsin), five biomarker candidates were selected for
follow-up screening on the basis of their apparent differential
expression in pooled sera from the EP group (MASP1, HBB and
ADIPO) or the VIUP group (PSG3 and PSG4) (Table 1). CRP
and FN1 were also included for follow-up screening on the basis of
SDS-PAGE results (Figure 1). However, shotgun proteomics
(Table 1) and analysis of CRP levels in individual sera (data not
shown) using an existing clinical assay (Clinical Chemistry unit,
Lothian University N.H.S. Trust, Royal Infirmary of Edinburgh)
did not support further analysis of CRP as a biomarker candidate.
Western Blot Validation of LC-ESI-MS/MS Data
Western blots of pooled whole sera and ProteoMinerTM
enriched fractions, probed with specific antibodies to proteins
identified by mass spectrometry (Tables 1), are shown in Figure 3
(full length images of individual blots are provided in Figure S1).
With the exception of HBB, pre-fractionation with ProteoMi-
nerTM affinity spin-columns resulted in enrichment of target
proteins. However, as predicted by SDS-PAGE (Figure 1. B3) and
shotgun proteomics (Table 1), HBB appeared to be increased in
whole serum from the EP group and was selected for follow-up
analysis. In contrast to the shotgun proteomics data (Table 1),
western blot analysis of ProteoMinerTM enriched fractions did not
support increased levels of MASP1 in serum from the EP group
Figure 1. 1D SDS-PAGE of ProteoMinerTM affinity-purified
serum, alongside the original whole sera and flow-through,
from women undergoing surgical management of EP (E),
surgical management of NVIUP (N) and surgical termination
of VIUP (V). Note the increased complexity and reduction in high
abundance proteins in the enriched fractions. Three bands (B1, B2 and
B3) appeared differentially expressed and were submitted for PMF.
doi:10.1371/journal.pone.0066974.g001
Fibronectin Reduced in Ectopic Pregnancy
PLOS ONE | www.plosone.org 2 June 2013 | Volume 8 | Issue 6 | e66974
(Figure 3). Instead, it supported a reduction in the 35 KDa
MASP1 light chain in both the EP and NVIUP groups. Given this
conflict with the shotgun proteomics data and technical difficulties
encountered with detecting MASP1 in whole serum, MASP1 was
excluded from follow-up analysis. Western blots for the remaining
four candidates (PSG3, PSG4, FN1 and ADIPO) produced results
that were consistent with the shotgun proteomics data. However,
the signal-to-noise ratio obtained for specific PSG3 labelling was
not sufficient for reliable measurement of PSG3 in individual
whole sera using western blot, and this candidate was not carried
through to further validation studies.
Western blots of individual whole sera from the retrospective
cohort were probed with antibodies specific for selected biomarker
candidates: HBB, ADIPO, FN1 and PSG4 (Figure 4). Nonpara-
metric one-way ANOVA (Kruskal-Wallis) detected significant
differences in FN1 (P,0.01) and PSG4 (P,0.0001) levels between
patient groups. Post-test non-parametric analysis identified signif-
icant decrease in FN1 and PSG4 levels in sera from the EP group
compared to the VIUP group (Mann Whitney test: P,0.01 and
,0.001 respectively). Additionally, there was a significant differ-
ence in FN1 levels between the EP and NVIUP groups (Mann
Whitney test: P,0.05). In contrast, PSG4 appears to be a marker
of viable intrauterine pregnancy, rather than EP, and was
significantly reduced (Mann Whitney test: P,0.05) in the NVIUP
group, when compared to the VIUP group. When receiver
operating characteristic (ROC) analysis of the ability of each
candidate to discriminate EP patients from both VIUP and
NVIUP patients was performed, both FN1 (Area under the ROC
curve 0.7765; 95% CI 0.6489 to 0.9041; P,0.01) and PSG4 (Area
under the ROC curve 0.8185; 95% CI 0.6909 to 0.9462; P,0.01)
appeared to have diagnostic value when applied to the retrospec-
tive cohort (Figure 4).
ELISA Analysis of Serum FN1 and PSG4
FN1 and PSG4 were selected for further validation in a
larger prospective cohort prospective cohort (n = 120): sera were
obtained from women (age 18–45 years) at the time of their first
clinical presentation with pain and/or bleeding prior to initial
diagnosis of a PUL. All women were monitored until their
discharge from hospital and their final pregnancy outcomes
were classified (Table 2: Table S2), as per the recent consensus
statement [22]. FN1 (Intra assay CV 1.08%; Inter Assay CV
6.29%; 150 ng/ml sensitivity 90%) and PSG4 (Intra assay CV
13.1%; Inter Assay CV 4.84%; 2 nM sensitivity 97%) compet-
itive ELISAs were developed and validated for use on human
serum samples. Nonparametric one-way ANOVA (Kruskal-
Wallis) did not detect significant differential expression of FN1
or PSG4 in the dEP group within the prospective cohort
(Figure 5: P.0.05). However, ROC analysis (Figure 5) of the
ability of FN1 to discriminate dEP patients from all the other
groups combined suggested that FN1 does have diagnostic
potential (Area under the ROC curve 0.6439; 95% CI 0.5090
to 0.7788; P.0.05), becoming significant when pEP and tPUL
are excluded from the analysis (Area under the ROC curve
Table 1. Candidate biomarkers identified by Shotgun LC-ESI-MS/MS.
Accession Name
Mascot
score EP
Mascot
score
NVIUP
Mascot
score VIUP
Peptides
EP
Peptides
NVIUP
Peptides
VIUP
SC [%]
EP
SC [%]
NVIUP
SC [%]
VIUP
MASP1_HUMANMannan-binding lectin serine
protease 1
151.32 73.31 15.42 4 2 1 8.30 3.72 2.15
HBB_HUMAN Hemoglobin subunit beta 144.49 62.83 0 7 1 0 29.93 8.84 0
FN1_HUMAN* Fibronectin 3548.02 4499.04 4025.33 164 205 233 39.19 45.47 43.76
ADIPO_HUMAN Adiponectin 123.88 158.21 101.96 5 6 5 23.37 21.72 15.57
PSG3_HUMAN Pregnancy-specific beta-1-
glycoprotein 3
0 0 110.01 0 0 5 0.00 0.00 6.78
PSG4_HUMAN Pregnancy-specific beta-1-
glycoprotein 4
0 27.84 110.37 0 1 5 0.00 2.63 7.40
CRP_HUMAN* C-reactive protein 377.27 289.61 333.71 21 7 10 27.68 20.98 27.23
LC-ESI-MS/MS data derived from pooled sera obtained from women prior to surgical management of definite ectopic pregnancy (EP), surgical management of definite
nonviable intrauterine pregnancy (NVIUP) and surgical termination of definite viable intrauterine pregnancy (VIUP) were used to interrogate the SwissProt database and
the results summarised in terms of: Mascot score; number of identified tryptic peptides; and sequence coverage (SC [%]). Following exclusion of potential
environmental contaminants, six candidate biomarkers were selected for follow-up screening on the basis of their apparent differential expression in pooled sera from
ectopic patients or women with viable intrauterine pregnancies.
*FN1 and CRP were included on the basis that they were identified to be down-regulated in pooled sera from ectopic patients by 1DGE (B1 and B2 Fig.1).
doi:10.1371/journal.pone.0066974.t001
Figure 2. Pooled sera from women undergoing surgical
management of EP, surgical management of NVIUP and
surgical termination of VIUP were affinity-purified using
ProteoMinerTM spin-columns and separated by 1D SDS-PAGE,
prior to trypsin digestion and LC-ESI-MS/MS. Interrogation of the
SwissProt database produced a total of 118 non-redundant high
confidence identities.
doi:10.1371/journal.pone.0066974.g002
Fibronectin Reduced in Ectopic Pregnancy
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0.6538; 95% CI 0.5158 to 0.7918; P,0.05). ROC analysis did
not support the use of PSG4 as a biomarker of ectopic
pregnancy in this cohort.
Discussion
Using a shotgun proteomics approach that incorporated
combinatorial ligand library pre-fractionation [21] to normalize
the dynamic range of serum protein concentrations, rather than
the more established approach of using panels of monoclonal
antibodies to deplete high abundance serum proteins [23], we
have identified FN1 as a potential adjunct diagnostic biomarker
for EP. Although our study is not the first to employ a shotgun
proteomics approach to ectopic pregnancy biomarker discovery
[20,24], it is the first to use the technique to compare sera from
patients with ectopic pregnancy, viable and non-viable intrauter-
ine pregnancy (Figure 2). The ability to differentiate an ectopic
pregnancy from a non-viable intrauterine pregnancy, and other
final PUL outcomes, will be critical to the success of any future
ectopic pregnancy diagnostic test. This study is also the first, to our
knowledge, that has tested the utility of potential ectopic
pregnancy biomarker candidates using prospectively collected first
presentation sera from an independent cohort of women with a
complete range of PUL final clinical outcomes (Figure 5).
Like biomarker candidates previously identified by our group
[17,25], both FN1 and PSG4 showed considerable promise as
biomarkers of ectopic pregnancy when assessed in the context of a
relatively simple retrospectively sampled cohort of women with
ectopic pregnancy, viable intrauterine pregnancy or non-viable
intrauterine pregnancy (Figure 4). However, ELISA analysis of
sera collected from women at their first clinical presentation with a
Figure 3. Western blots of pooled whole sera and ProteoMinerTM affinity-purified serum from women undergoing surgical
management of EP, surgical management of NVIUP and surgical termination of VIUP were probed with antibodies specific for
proteins identified by LC-ESI-MS/MS (Table 1).
doi:10.1371/journal.pone.0066974.g003
Figure 4. Western blots of individual whole sera from women undergoing surgical management of EP, surgical management of
NVIUP and surgical termination of VIUP were probed with antibodies specific for: HBB; ADIPO; FN1; and PSG4. Integrated density
values of specifically labelled bands were normalised against a positive control (pooled VIUP serum). ROC curves were generated for ectopic vs non-
ectopic patient groups.
doi:10.1371/journal.pone.0066974.g004
Fibronectin Reduced in Ectopic Pregnancy
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PUL (Figure 5) revealed a less marked reduction in FN1 and PSG4
serum levels in women who required surgical intervention for an
ectopic pregnancy (Figure 4). Nevertheless, ROC analysis
suggested that serum FN1 levels may be useful in differentiating
ectopic pregnancy from other pregnancy outcomes (Figure 5), with
its diagnostic value becoming significant (Area under the ROC
curve 0.6538; 95% CI 0.5158 to 0.7918; P,0.05) when the
medically managed PUL outcomes, for which a definitive final
diagnosis was not possible (pEP and srPUL), were excluded from
the analysis (Figure 5). This reduction in diagnostic value, when
applied to a ‘real world’ cohort of patients demonstrates the
importance of study design.
A previous proteomics study [20] identified a disintegrin and
metalloprotease-12 (ADAM-12) as a potential ectopic pregnancy
biomarker, which has since been validated in a sera from a larger
cohort of women with ectopic pregnancy or viable intrauterine
pregnancy, collected at the time of presentation at emergency
departments with pelvic pain and/or bleeding and a positive
pregnancy test, and appears to be able to differentiate ectopic
pregnancy from viable intrauterine pregnancy with a good degree
of sensitivity and specificity [26]. We did not identify ADAM-12 as
a potential biomarker for ectopic pregnancy in our study, possibly
due to differences in the sensitivity of the systems used and/or pre-
fractionation methods, or possibly due to the inclusion of our non-
viable intrauterine pregnancy control group. However, when we
recently attempted to test ADAM12 as a biomarker for ectopic
pregnancy in the same cohort of patients with a PUL used in the
current study [27], we could not replicate the findings of Rausch
et al [26]. Crucially, serum levels of ADAM12 were virtually
identical in women with srPUL and dEP, groups that require very
different clinical management. Gestational age is likely to be a key
factor in ADAM12 levels, as it rises exponentially from around
week 5 of the first trimester [28]. Therefore, it seems possible that
the lower levels of ADAM12 we reported [27] reflect the relatively
early gestational age of our prospectively collected first presenta-
tion PUL cohort. There is also debate as to the specificity of
ADAM-12 with regard to differentiating ectopic pregnancy from
outcomes other than viable intrauterine pregnancy [29] and its
clinical utility remains unclear at this time. When compared
directly, FN1 appears to have greater potential that ADAM12 in
identifying women who require surgical intervention for an ectopic
pregnancy at their first presentation with a pain and/or bleeding
and a PUL.
It was interesting that both our proteomics study, and the
previous proteomics study [20,24], identified differences in serum
levels of pregnancy-specific beta-1-glycoproteins (specifically
PSG4/9) consistent with older published data [30,31]. However,
in our study this finding became no longer significant when we
included dNVIUP and/or other PUL groups in our analysis. It is
possible that this is due to a difference in the assays used to detect
PSG, however we believe it is also a function of and demonstration
of the importance of a study design including these additional
clinical categories.
While we believe that our findings are important, we
acknowledge that our prospectively collected cohort is small and
FN1 does not appear to have sufficiently high specificity and
sensitivity as a diagnostic biomarker in isolation. The diagnosis of
ectopic pregnancy requires both very high specificity and
sensitivity given that a false negative could lead to serious
morbidity and potential mortality. Similarly, a false positive result
could lead to the termination of a viable pregnancy and we agree
with other investigators in the field that the best future test will
almost certainly be a multiplexed assay specific for a panel of
biomarkers [7]. Recent analysis of the performance of a multiple
marker test based on four existing biomarkers candidates
(progesterone, VEGF, inhibin A and activin A) has produced
encouraging results [32]. Nonetheless, there remains the key
question of differentiating ectopic pregnancy from PUL outcomes
other than viable intrauterine, and such a test might benefit from
inclusion of FN1. Furthermore, our findings suggest that further
scrutiny of changes in components of the pathways involved in
regulation of serum FN1 levels and/or sequestration of FN1
during pregnancy [33] may provide additional, more robust
candidate biomarkers of ectopic pregnancy. It will be of interest to
determine whether changes in FN1 levels associated with ectopic
pregnancy are more marked in plasma, compared to serum where
the majority of FN1 is sequestered during the coagulation process.
Table 2. Patient recruitment: 120 patients with an initial diagnosis of a PUL were recruited to the study and grouped according to
final pregnancy outcomes.
Group Inclusion criteria hCG (mU/ml) Age (years) BMI n
dVIUP Definite viable intrauterine pregnancy: TVUSS confirmation of intrauterine gestational
sac with yolk sac and embryo with cardiac activity.
684462017 2861 2662 28
dNVIUP Definite nonviable intrauterine pregnancy: USS confirmation of intrauterine gestational
sac with yolk sac and/or embryo without cardiac activity seen prior to uterine
evacuation. Confirmed by histopathology.
402261904 3261 2761 26
dEP Definite ectopic pregnancy: intervention prompted by adnexal mass on TVUSS or by
abnormal rise in serum hCG levels and confirmed at surgery and by histopathology.
11516238 2961 2561 17
NP Not pregnant: positive home pregnancy test result subsequently not confirmed
by serum hCG measurement.
,5 2662 2763 11
srPUL Spontaneously resolving PUL: PUL with spontaneous resolution of serum hCG levels. 4286114 3261 2861 27
tPUL Treated persistent PUL: abnormal rise in serum hCG levels but no adnexal mass or IU
sac seen on TVUSS after monitoring, managed medically with methotrexate.
4006188 3264 2865 3
pEP Probable ectopic pregnancy: inhomogenous adnexal mass or extrauterine sac-like
structure on TVUSS managed medically with methotrexate.
5976200 3361 2561 8
doi:10.1371/journal.pone.0066974.t002
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Figure 5. FN1 and PSG4 ELISA of serum collected at first presentation of women with a PUL, categorized according to final
pregnancy outcome: dNVIUP (n=26); dVIUP (n=28); dEP (n=17); NP (n=11); srPUL (n=27); pEP (n=8); and tPUL (n=3). ROC curves
were generated for ectopic vs non-ectopic patient groups. Analysis was repeated after ambiguous medically treated PUL outcomes (pEP and tPUL)
were excluded (-PUL Data).
doi:10.1371/journal.pone.0066974.g005
Fibronectin Reduced in Ectopic Pregnancy
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Materials and Methods
Ethical Approval
Ethical approval for this study was obtained from the Lothian
Research Ethics Committee (LREC 04/S1103/20 and 09/
S1103/39), with informed written consent obtained from patients.
Setting
Patients were recruited from the Pregnancy Support Centre at
the Royal Infirmary of Edinburgh from March 2010 to January
2011.
Patient Groups
Retrospective cohort (n = 40): sera were obtained from women
(aged 18–45 years) at time of surgery: undergoing surgical
termination of viable intrauterine pregnancy (USS-confirmed
intrauterine gestational sac with an embryo with cardiac activity
seen prior to uterine evacuation); surgical management of
nonviable intrauterine pregnancy (USS-confirmed intrauterine
gestational sac with yolk sac and/or embryo without cardiac
activity seen prior to uterine evacuation, n= 10); and surgical
management of ectopic pregnancy (confirmed at surgery and by
pathology, n= 15).
Prospective cohort (n = 120): sera were obtained from women
(age 18–45 years) at the time of their first clinical presentation with
pain and/or bleeding prior to initial diagnosis of a PUL. All
women were monitored until their discharge from hospital and
their final pregnancy outcomes were classified (Table 1), as per the
recent consensus statement [22].
Sample Pre-fractionation and One Dimensional Gel
Electrophoresis
Pooled sera from the retrospective cohort were pre-fractionated
using ProteoMinerTM affinity spin-columns (BioRad laboratories,
Hertfordshire, UK) following the manufacturers instructions. 5 mg
of pooled whole sera, ProteoMinerTM flow-through and Proteo-
MinerTM enriched fractions from each sample were separated by
one dimensional gel electrophoresis (1DGE: NuPAGE 4–12% Bis-
Tris gels (Invitrogen)). Gels were stained with Imperial Protein
stain (Thermo Scientific, Rockford, USA) as per the manufactur-
ers instructions.
Targeted Peptide Mass Fingerprinting
Where 1DGE revealed gross differences between patient groups
in the instructive cohort, differentially expressed bands were
submitted for peptide mass fingerprinting (PMF). Selected bands
were digested with trypsin and PMF was performed by Matrix-
assisted laser desorption/ionization time-of-flight mass spectrom-
etry (MALDI-TOF: UltraflexTM II, Bruker Daltonics, Bremen,
Germany). Band identity was determined by database searches of
SwissProt using the Mascot search algorithm (http://www.
matrixscience.com: using ‘‘homo sapiens’’ as a taxonomical search
parameter; mass tolerance of 60?15 Da; and fixed modifica-
tion=Cys-carbamidomethylation). Where MALDI-TOF results
were not definitive, PMF was performed by liquid chromatogra-
phy electrospray ionization tandem mass spectrometry (LC-ESI-
MS/MS) as previously described [34]. Following deconvolution of
raw MS/MS data, database searches of SwissProt, using ‘‘homo
sapiens’’ as a taxonomical search parameter, were performed via
ProteinScapeH software (Bruker) and the Mascot search algorithm
(Matrix Science). Proteins identities were assigned higher confi-
dence if two or more of their predicted unique tryptic peptides,
with MS/MS spectra containing four or more contiguous ‘y’ or ‘b’
ions, were detected.
Shotgun LC-ESI-MS/MS
1DGE was performed on ProteoMinerTM enriched fractions
from each patient group in the instructive cohort. Lanes
corresponding to EP, NVIUP and VIUP patient groups were
divided into 27 slices, subjected to standard in-gel trypsinolysis and
LC-ESI-MS/MS as described above.
Western Blot Analysis
1DGE was performed on ProteoMinerTM enriched pooled sera
and whole sera (pooled and individual samples). Gels were blotted
onto Immobilon-P membrane (Millipore, Livingston, UK) using a
Transblot-SD (Bio-Rad Laboratories, Hemel Hempstead, UK).
After blocking for 30 minutes in staining buffer (Tris buffered
saline +0.5% Tween-20+2% fat-free milk powder), blots were
incubated for 2 hours with: 1 mg/ml of rabbit anti-Mannan
binding lectin serine protease 1 (Abcam, Cambridge, UK); 30 ng/
ml of rabbit anti-FN1 (Sigma); 1 mg/ml of rabbit anti-Pregnancy
specific beta 1 glycoprotein 3 (Abcam); 1 mg/ml of control rabbit
IgG (Abcam); a 1 in 1500 dilution of mouse polyclonal anti-
Pregnancy specific beta 1 glycoprotein 4 (Abcam); a 1 in 1500
dilution of normal mouse serum (Sigma); 1 mg/ml of monoclonal
mouse anti-Adiponectin IgG1 (Abcam); 1 mg/ml of monoclonal
mouse anti-Hemoglobin subunit beta IgG1 (Abcam); or 1 mg/ml
of control Mouse IgG1 (Sigma). Blots were washed (six three
minute changes of Tris buffered saline +0.5% Tween-20) and
incubated for 1 hour with the 20 ng/ml of appropriate Alkaline
phosphatase (ALKP) conjugated secondary antibodies (Stratech
Scientific, Newmarket, UK). Following washing, specific ALKP
labelling was detected using CDP-STAR Star (Boehringer-
Mannheim, Bracknell, UK). Images were acquired using a
VersaDocTM Imaging System (Bio-Rad Laboratories) and specific
Chemiluminescence was measured using ImageJ [35], and
expressed as relative to a positive control included in each gel
(pooled VIUP serum).
FN1 ELISA
Purified human FN1 (Sigma) was biotinylated using an EZ-
LinkH Sulfo-NHS-Biotin kit (Thermo Shandon; Runcorn, UK).
MICROLONH 200 96-well microplates (Greiner Bio-One, Stone-
house, UK) were coated overnight at 4uC with 50 ml/well of rabbit
anti-human FN1 (Sigma) diluted to 50 ng/ml in 0.2 M NaHCO3/
Na2CO3 buffer (pH 9.6). Plates were washed (six washes with
0.15 M NaCl +0.05% Tween-20) and blocked for 1 hour at 21uC
with 100 ml/well of ELISA buffer (Tris buffered saline +0.5%
Tween-20+4% bovine serum albumin). Purified human FN1
standards (150 ng/ml –10 mg/ml) and serum samples (diluted 1 in
10 in ELISA buffer) were incubated for 10 minutes with equal
volumes of biotinylated-FN1 (1 mg/ml). Plates were washed and
incubated for 1 hour at 21uC with 50 ml/well of biotinylated-FN1/
standards and biotinylated-FN1/serum samples. Plates were
washed and incubated for 30 minutes with ultrasensitive
streptavidin-peroxidase polymer (Thermo Fisher Scientific, Cram-
lington, UK) diluted to 1 in 10000 in ELISA buffer. After washing,
plates were incubated with 50 ml/well of SureBlueTM peroxidase
substrate (KPL, Inc., Maryland, USA) for 15 minutes before the
reaction was stopped with 100 ml/well of 0.1 M HCl and the
absorbance of the product measured at 450 nm.
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PSG4 ELISA
MICROLONH 200 96-well microplates were coated overnight
at 4uC with 50 ml/well with 250 nM PSG4 peptide (sc-240791 P:
Santa Cruz Biotechnology, Inc. Heidelberg, Germany) in 0.2 M
NaHCO3/Na2CO3 buffer (pH 9.6). Plates were washed and
blocked for 1 hour at 21uC with 100 ml/well of ELISA buffer.
PSG4 peptide standard (256 nM –2 nM) and serum samples were
incubated for 10 minutes with equal volumes of 0.2 mg/ml of goat
anti-PSG4 (Santa Cruz Biotechnology, Inc.). Plates were washed
and incubated for 1 hour at 21uC with 50 ml/well of goat anti-
PSG4/standards and goat anti-PSG4/serum samples. After
washing, plates were incubated for 1 hour at 21uC with 50 ml/
well of 200 ng/ml of biotinylated donkey anti-goat (Abcam). Plates
were washed and incubated for 30 minutes with ultrasensitive
streptavidin-peroxidase polymer diluted to 1 in 10000. After
washing, plates were developed as described above.
Statistical Analysis
Statistical analyses, ELISA standard curve formulae and
receiver operating characteristic (ROC) curves were generated
using Prism (GraphPad Software, La Jolla, USA).
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